针对T细胞急性淋巴细胞白血病的TCR前向免疫治疗
Patricia Fuentes1, Marina García-Peydró1, Juan Alcain1
1Immune System Development and Function Unit. Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC) and Universidad Autónoma de Madrid (UAM), Madrid, Spain.
Nature immunology
|September 1, 2025
概括
针对T细胞前受体 (TCR) 提供了针对T细胞急性淋巴细胞白血病 (T-ALL) 的新免疫疗法. 在临床前模型中,这种方法有效抑制白血病发起细胞和瘤生长.
科学领域:
- 免疫学
- 癌症学
- 分子生物学
背景情况:
- T细胞急性淋巴细胞白血病 (T-ALL) 是一种侵袭性癌症,对于复发/耐药病例的治疗选择有限.
- 由于白血病和正常T细胞之间共享抗原,因此很难准T-ALL.
- 白血病发起细胞 (LIC) 驱动T-ALL的进展,是关键的治疗点.
研究的目的:
- 为了确定T-ALL LIC的新生物标志物.
- 评估T细胞前受体 (TCR前) 作为T-ALL的治疗点.
- 在T-ALL中开发和验证针对TCR的向免疫疗法.
主要方法:
- 在人体样本中识别TCR前作为T-ALL LIC生物标志物.
- 在老鼠异种移植中进行功能丧失的遗传研究,以评估TCR前信号的必要性.
- 开发和体内验证抗pTα单克隆抗体和抗体与药物结合疗法.
主要成果:
- 预TCR是T-ALLLIC的特定生物标志物.
- 在T-ALL LIC活性和瘤进展方面,TCR前信号是必不可少的.
- 抗pTα抗体与药物结合疗法在体内有效抑制LIC和T-ALL的进展.
结论:
- 预T细胞受体是T-ALL的可行和特定的治疗点.
- 用抗体与药物结合物向TCR显示为对T-ALL的有力免疫疗法.
- 这一策略为表达TCR前的复发/耐药T-ALL患者提供了潜在的新疗法.
更多相关视频
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.2K
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.4K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Cytotoxic T Cells-mediated Immune Response
1.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.9K
